Spanish Registry for Adverse Events of Biological Therapy in Rheumatic Diseases (BIOBADASER): State Report, January 26th, 2006

Lipani, 2001, A proposal for developing a large patient population cohort for longterm safety monitoring in rheumatoid artritis, J Rheumatol, 28, 1170 Carmona, 2003, Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity, Ann Rheum Dis, 62, 897, 10.1136/ard.62.9.897 2002, Rev Esp Reumatol, 29, 292 Gómez-Reino, 2003, Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report, Arthritis Rheum, 48, 2122, 10.1002/art.11137 Caminero, 2003, Evaluation of tuberculosis trends in Spain, 1991–1999, Int J Tuberc Lung Dis, 7, 236 Bresnihan, 2003, Infection complications associated with the use of biologic agents, Rheum Dis Clin North Am, 29, 185, 10.1016/S0889-857X(02)00101-1 Kroesen, 2003, Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy, Rheumatology, 42, 617, 10.1093/rheumatology/keg263 Ellerin, 2003, Infections and anti-tumor necrosis factor therapy, Arthritis Rheum, 48, 3013, 10.1002/art.11301 Weisman, 2002, What are the risks of biologic therapy in rheumatoid arthritis? An update on safety, J Rheumatol, Suppl65, 33 Agencia del Medicamento y Productos Sanitarios. Nota informativa de la Agencia Española del Medicamento sobre riesgo de medicamentos. Ref: 2002/01. February 2002 [cited 13 Feb 2005]. Available from: www.agemed.es/documentos/notasPrensa/csmh/2002/cont_Infliximab_feb02_ps.htm Carmona, 2005, Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists, Arthritis Rheum, 52, 1766, 10.1002/art.21043